AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06228235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: rTMS: rTMS is a form of non-invasive brain modulation. High-frequency rTMS will be administered. Pulses will be delivered at the frequency of 20Hz, in 50 trains of 40 pulses, 2000 pulses in total.~Behavioral priming with regulation of craving: During rTMS, participants will look at pictures either related or unrelated to smoking. When looking at pictures related to smoking, participants will either upregulate cravings by thinking about the immediate positive experience of smoking or downregulate cravings by thinking about long-term negative consequences of smoking. When looking at neutral pictures unrelated to smoking, participants will not regulate their cravings.
Study NCT06258707 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LuxBoost IOL
Description: Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.
Study NCT06258707 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LuxGood IOL
Description: Bilateral implantation in the capsular bag to replace the cataractous human crystalline lens.
Study NCT06515626 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cell reinfusion
Description: Subjects were identified according to their benefit from the first treatment and target expression Whether to accept multiple returns; CAR-T cell reinfusion dose was 1\~10×106 cells/kg, and the reinfusion dose could be adjusted according to the tolerance of the subjects Usually intravenous infusion, but also according to the need for local interventional treatment or injection treatment
Study NCT06417541 — intervention group
Intervention type: RADIATION
Intervention: Living patients with an indwelling central venous catheter referred to a CT scan without iv contrast
Description: Patients will be investigated using a photon counting CT. Prior to the investigation patients will be investigated with ultrasound. The results from the two modalities will be compared
Study NCT06097975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV
Description: Participants will receive neo-adjuvant administration of intravenous immunotherapy on day 1 + day 22: ipilimumab + nivolumab IV.
Study NCT06097975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurosurgery and intracavitary injection nivolumab and ipililumab
Description: The neo-adjuvant therapy will be followed by a maximal safe surgery resection of the glioblastoma. Immunotherapy (nivolumab + ipililumab) will be injected into the brain tissue, followed by insertion of an Ommaya reservoir
Study NCT05348954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EX-PLISSIT MODEL
Description: The content of the program will include information about the anatomy and physiology of the male-female reproductive system, sexuality and sexual cycle physiology, factors affecting sexuality, postpartum changes, hormonal changes, breastfeeding and their effects on sexuality, and methods of contraception.
Study NCT05230355 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 360 degrees subthreshold diode laser cyclophotocoagulation
Description: cyclophotocoagulation is applied along 360 degrees over pars plana
Study NCT05230355 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 180 degrees subthreshold diode laser cyclophotocoagulation
Description: cyclophotocoagulation is applied over one hemisphere only along 180 degrees in a double arc fashion
Study NCT06454123 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OTX-401
Description: Evidence-based treatments for obesity and binge eating
Study NCT06451666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine HCl Ophthalmic Solution
Description: Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days
Study NCT06451666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle, one drop in each eye, once daily, for up to 30 days.
Study NCT05516238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Case management
Description: Case management cover therapy (psychotherapy/psychoeducation), medication adjustment, training in daily living skills (supportive), and direct consultations in crises.
Study NCT05516238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case management
Description: Case management cover therapy (psychotherapy/psychoeducation), medication adjustment, training in daily living skills (supportive), and direct consultations in crises.
Study NCT06045611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isolated Pea Protein
Description: Participants will consume the protein supplement dissolved in water in an opaque mug wearing a nose clip.
Study NCT06045611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isolated Whey Protein
Description: Participants will consume the protein supplement dissolved in water in an opaque mug wearing a nose clip.
Study NCT06045611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isolated Faba Bean Protein
Description: Participants will consume the protein supplement dissolved in water in an opaque mug wearing a nose clip.
Study NCT06045611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will consume the placebo in an opaque mug wearing a nose clip.
Study NCT06326086 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy drug
Description: Chemotherapy drug as prescribed by primary treating physician
Study NCT06326086 — intervention group
Intervention type: DRUG
Intervention: Targeted Agent
Description: Targeted agents as prescribed by primary treating physician
Study NCT06097975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant nivolumab IV + nivolumab and ipililumab intracavitary
Description: Postoperatively, administration of immunotherapy will be continued, on day 15 postoperatively and every 2 weeks thereafter patients will receive nivolumab IV as well as ipililumab + nivolumab intracavitary.
Study NCT06326086 — intervention group
Intervention type: DRUG
Intervention: Immunotherapy
Description: Immunotherapy as prescribed by primary treating physician
Study NCT06458907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TricValve® Transcatheter Bicaval Valve System
Description: TricValve® Device (Device) Group subjects will undergo TricValve® implantation and will continue to be managed with optimal medical therapies.
Study NCT06458907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical therapy
Description: Optimal medical therapy
Study NCT06458907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal medical therapy
Description: Optimal medical therapy
Study NCT05734560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D2C7-IT
Description: D2C7-IT will be dosed at 166,075 ng in 36 mL.
Study NCT05734560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2141-V11
Description: 2141-V11 will be dosed at 3 mg in 3.5 mL for CED administration. 2141-V11 in the cervical perilymphatic subcutaneous area will be dosed at 2 mg.
Study NCT06369246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo Radiation Therapy
Study NCT06632301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Primary hip replacement with cementless stem
Description: Total Hip Arthroplasty is today one of the most established surgical orthopaedic procedures worldwide.
Study NCT06488898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic adipose tissue-derived mesenchymal stem cells
Description: Investigational medicinal product: Allogeneic adipose tissue-derived mesenchymal stem cells and expanded, which are considered an advanced therapy medicinal product under European regulation (Article 2(1) of Regulation (EC) No 1394/2007 of the European Parliament and the Council of November 13 th 2007 about advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004).~Administration form: Local injection by means of a catheter placed inside the previously excluded aneurysmal sac.~Administration dose: 1x10000000 cells/kg patient weight.~Administration guidelines: single infusion on the endovascular day AAA intervention.
Study NCT05588752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAP block
Description: TAP block under ultrasound
Study NCT05703334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio tap
Description: Applied on pulmonary muscles :diaphragm muscle and abdominal muscle and sternocleinomastoid muscle 3 time per weak for 2 mounth
Study NCT06259149 — intervention group
Intervention type: DRUG
Intervention: Nardraparin calcium injection
Description: The dose of nardraparin calcium injection is 100AxaIU/kg, adjusted according to the patient's body weight, and is injected subcutaneously once a day
Study NCT05365815 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Melanated Group Midwifery Care
Description: Racially concordant maternity care Group prenatal care Racially concordant nursing care coordination Postpartum doula support
Study NCT05102071 — intervention group
Intervention type: DRUG
Intervention: empagliflozin
Description: empagliflozin
Study NCT05102071 — intervention group
Intervention type: DRUG
Intervention: metformin
Description: metformin
Study NCT05102071 — intervention group
Intervention type: DRUG
Intervention: sulfonylurea
Description: sulfonylurea
Study NCT06162468 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided pancreatic cyst chemoablation (EUS-PCA) using gemcitabine and paclitaxel
Description: EUS-PCA using gemcitabine and paclitaxel
Study NCT06504732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IAH0968
Description: Subjects were treated with IAH0968 in combination with or without the CAPEOX regimen in the corresponding groups. Every 3 weeks was defined as a treatment cycle and IAH0968 was used for a maximum of 35 cycles.
Study NCT06489548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foralumab TZLS-401 50 µg
Description: Foralumab is a nasal anti-CD3 antibody. It will be administered in doses of 50 µg vs. placebo.
Study NCT06489548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foralumab TZLS-401 100 µg
Description: Foralumab is a nasal anti-CD3 antibody. It will be administered in doses of 100 µg vs. placebo.
Study NCT05650710 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nerve stimulation using nerve stimulation device and sterile wire electrode.
Description: A nerve stimulator device will be used in this study as a research tool to investigate whether a future (currently nonexistent) medical device might be able to stimulate desired infrahyoid musculature in a therapeutic manner.
Study NCT06123338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered on an every 3-week dosing schedule
Study NCT06123338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered on an every 3-week dosing schedule
Study NCT06123338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin every 3 weeks, +/-7 days
Study NCT06123338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine twice daily on days 1 to 14 every 3 weeks or 5-FU on days 1 to 5 every 3 weeks
Study NCT05875961 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose A/H2N3c + standard dose MF59
Description: Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
Study NCT05875961 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intermediate dose A/H2N3c + standard dose MF59
Description: Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
Study NCT05875961 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose A/H2N3c + standard dose MF59
Description: Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
Study NCT05875961 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose A/H2N3c non-adjuvanted
Description: Two intramuscular injections (3 weeks apart) of cell culture-derived non-adjuvanted H2N3 vaccine
Study NCT05875961 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lowest dose A/H2N3c + high dose MF59
Description: Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
Study NCT05875961 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose A/H2N3c + high dose MF59
Description: Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
Study NCT06506604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLEVER
Description: CLEVER: A positive body image-based intervention for Chronic Low Back Pain.~Patients will receive 4 sessions to approach 5 clinical modules: Pain Psychoeducation, Body Awareness, Pain Acceptance, Body Appreciation and Functionality and Gratitude. virtual reality environments will be used to enhance the clinical outcomes in two sessions. Each session will last 60 minutes.
Study NCT06316843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir celecoxib dose 1
Description: 1500 mg valacyclovir 200 mg celecoxib taken two times a day
Study NCT06316843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir celecoxib dose 2
Description: 750 mg valacyclovir 200 celecoxib mg taken two times a day
Study NCT06316843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules colored matched to investigational product taken two times a day
Study NCT06202053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type of surgical incision
Description: The experimental group (patients received periareolar incision):~An arc-shaped incision was made on the lateral side of the patient's affected areola. The subcutaneous tissue was then dissociated between the lateral mammary gland and the skin to the level of the fourth intercostal space in front of the midaxillary line. The fatty tissue behind the breast was separated horizontally to expose the serratus anterior muscle, and an intercostal incision was made. The skin was pulled back throughout the procedure to expose a better surgical field and avoid damage to the mammary gland.~The control group (patients underwent an axillary incision):~For patients in the control group, an incision was made into the fourth intercostal space in the midline of the axilla, where subcutaneous tissue was separated and entered the chest.
Study NCT06470100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: unilateral administration of 20ml of 0,2% ropivacaine + 2ml 0.9% sodium chloride for the erector spine plane block
Study NCT06470100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: unilateral administration of 20ml of 0,2% ropivacaine with 4mg Dexamethasone for the erector spine plane block
Study NCT06470100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: unilateral administration of 20ml of 0,2% ropivacaine with 50ug Dexmedetomidine for the erector spine plane block
Study NCT06635447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: 400 mg, oral, twice daily; 4 days on and 3 days off
Study NCT06635447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant IV
Study NCT05273749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL Tablet, 5.6 mg
Description: Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Study NCT05273749 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SL Tablet
Description: Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Study NCT05421325 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QBKPN SSI
Description: Site-Specific Immunomodulator
Study NCT05421325 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Placebo
Description: Normal Saline
Study NCT05876858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to four weeks depending on subject, imaging agent and scanner availability. Subjects will be asked to complete the HEAL questionnaires before or after their PET/CT scan on each day.
Study NCT05876858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-butanol
Description: Each subject will undergo a dynamic 18F-FDG PET/CT scan (this drug is FDA approved) and a dynamic 11C-butanol PET/CT scan (this drug is under an IND) on the EXPLORER total-body PET/CT system. The two scans will be performed on the same day or within a period of up to four weeks depending on subject, imaging agent and scanner availability. Subjects will be asked to complete the HEAL questionnaires before or after their PET/CT scan on each day.
Study NCT05909111 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: MRI weekly during the radiation treatment course (5 RMI added to the standard care)
Study NCT05081713 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: high-intensity training focused on stepping in variable contexts
Description: Approximately 10 weeks (\~30 sessions) of high-intensity training
Study NCT04710576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Axatilimab is a high-affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor-derived macrophages that mediate the disease processes involved in cGVHD.
Study NCT04618016 — intervention group
Intervention type: DEVICE
Intervention: UHMWPE with Vitamin E
Description: e.motion Pro (PS and UC) with MXE gliding surface
Study NCT04618016 — intervention group
Intervention type: DEVICE
Intervention: UHMWPE without Vitamin E
Description: e.motion Pro (PS and UC) with β-PE gliding surface
Study NCT05515367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desidustat
Description: Oral tablet
Study NCT06258889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: reward-focused intervention
Description: Participants complete three interventions based on the Positive Affect Treatment:~* Finding the silver lining includes attending to and appreciating positive aspects of past events~* Taking ownership includes identifying the personal behavioral contribution to rewarding past experiences~* Imagining the positive includes training the prospective, positive imagination of future events~Participants are asked to practice these interventions at least three times a week (approx. 15 mins each) until the next training session.
Study NCT06258889 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive flexibility intervention
Description: This training aims to promote cognitive flexibility in the context of public speaking situations. The intervention is based on the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders.~Participants will be trained to identify and modify non-adaptive thoughts occurring in the context of public speaking situations.
Study NCT06258889 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exposure
Description: All participants undergo an exposure training session lasting approximately 90 minutes, which includes three exposure trial where participants give a speech, each lasting 5 minutes.~Exposure exercises are enriched with interventions of the respective treatment group (either reward-focused or cognitive flexibility interventions).
Study NCT06258889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exposure
Description: All participants undergo an exposure training session lasting approximately 90 minutes, which includes three exposure trial where participants give a speech, each lasting 5 minutes.~Exposure exercises are enriched with interventions of the respective treatment group (either reward-focused or cognitive flexibility interventions).
Study NCT06258889 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: All participants received information on anxiety, and the maintenance of anxiety as well as a rationale for the exposure session.
Study NCT06258889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: All participants received information on anxiety, and the maintenance of anxiety as well as a rationale for the exposure session.